NDC 73309-025-01 - Cefpodoxime Proxetil
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 73309-025
- Requested NDC
- 73309-025-01
- Package NDCs from labels
- 73309-025-01, 73309-025-02, 73309-025-03
- Manufacturer
- BLUEBAY SHANDONG CO.,LTD
- Effective date
- 2021-10-28
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cefpodoxime Proxetil - BLUEBAY SHANDONG CO.,LTD | BLUEBAY SHANDONG CO.,LTD | 2021-10-28 | BULK INGREDIENT |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 73309-025-01 | Cefpodoxime Proxetil | 500 g in 1 PACKAGE | POWDER | 500 | 3 | |
| 73309-025-02 | Cefpodoxime Proxetil | 250 g in 1 JAR | POWDER | 250 | 3 | |
| 73309-025-03 | Cefpodoxime Proxetil | 50 g in 1 JAR | POWDER | 50 | 3 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CEFPODOXIME PROXETIL | CEFPODOXIME PROXETIL | Redpharm Drug | 59d848e9-de7a-669b-e063-6394a90a2b35 | 2026-08-25 | Warnings, Adverse reactions | 2TB00A1Z7N |
| Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | Sandoz Inc | 8519a9d8-7106-4545-bc58-859ee9a6708e | 2026-07-30 | Warnings, Adverse reactions | 2TB00A1Z7N |
| Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | REMEDYREPACK INC. | dae9cbf2-65b5-49fa-898b-924c39b86c57 | 2026-06-04 | Warnings, Adverse reactions | 2TB00A1Z7N |
| Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | Rising Pharma Holdings, Inc. | edf589b2-f796-4522-a5e6-2bd0a833922f | 2025-06-06 | Warnings, Adverse reactions | 2TB00A1Z7N |
| Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | Golden State Medical Supply, Inc. | fb313728-09f1-aff8-e053-6394a90a30a8 | 2025-02-18 | Warnings, Adverse reactions | 2TB00A1Z7N |
| Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | NuCare Pharmaceuticals,Inc. | fe827f61-9336-72e7-e053-6394a90af75f | 2025-02-06 | Warnings, Adverse reactions | 2TB00A1Z7N |
| Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | NuCare Pharmaceuticals,Inc. | 1b405104-650b-c8e3-e063-6294a90a9e8a | 2024-06-19 | Warnings, Adverse reactions | 2TB00A1Z7N |
| CEFPODOXIME PROXETIL | CEFPODOXIME PROXETIL | Cronus Pharma LLC | bc9c338c-1fc7-4bc2-a357-a78e433cbe9d | 2024-01-04 | Warnings, Adverse reactions | 2TB00A1Z7N |
| Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | NorthStar Rx LLC | 5310de78-22c3-4bee-9956-854e767b6bef | 2024-01-04 | Warnings, Adverse reactions | 2TB00A1Z7N |
| Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | Aurobindo Pharma Limited | 63777889-d306-4fc3-88da-b24859040ef4 | 2024-01-04 | Warnings, Adverse reactions | 2TB00A1Z7N |
| CEFPODOXIME PROXETIL | CEFPODOXIME PROXETIL | Aurobindo Pharma Limited | c36f2137-98bb-4583-89f7-6bce9582c465 | 2024-01-03 | Warnings, Adverse reactions | 2TB00A1Z7N |
| CEFPODOXIME PROXETIL | CEFPODOXIME PROXETIL | NorthStar Rx LLC | 4587a7c1-cd6c-4946-a0dd-fcfe0c8504b9 | 2024-01-03 | Warnings, Adverse reactions | 2TB00A1Z7N |
| Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | Amici Pharmaceuticals, LLC. | 9d6d7f50-9838-47e3-8214-53e2dbeeadea | 2023-07-13 | Warnings, Adverse reactions | 2TB00A1Z7N |
| Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | Ascend Laboratories, LLC | ce5646cb-a450-4c2c-8499-6ecf71b12b0e | 2023-04-14 | Warnings, Adverse reactions | 2TB00A1Z7N |
| Cefpodoxime Proxetil | CEFPODOXIME PROXETIL | Ascend Laboratories, LLC | 5d5ca5b6-282b-4683-908c-854782255739 | 2022-05-20 | Warnings, Adverse reactions | 2TB00A1Z7N |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.